版本:
中国

BRIEF-Audentes Therapeutics qtrly loss per share $0.83

May 11 Audentes Therapeutics Inc

* Audentes therapeutics reports first quarter 2017 financial results and provides corporate update

* Qtrly loss per share $ 0.83

* Q1 earnings per share view $-0.92 -- Thomson Reuters I/B/E/S

* Audentes therapeutics inc - research and development expenses were $14.6 million for q1 of 2017 compared to $7.9 million for same period in 2016

* Audentes therapeutics inc - as of march 31, 2017, audentes had cash, cash equivalents and short-term investments of $81.7 million

* Audentes therapeutics inc - current cash, cash equivalents and marketable securities are planned to fund operations into late 2019

* Audentes therapeutics-on track to file inds to evaluate systemic administration of at982 for treatment of pompe disease, at307 for treatment of cpvt Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐